2024
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature
Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M, Potenza M, Angarita G. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature. Expert Opinion On Pharmacotherapy 2024, 26: 133-146. PMID: 39708346, PMCID: PMC11786980, DOI: 10.1080/14656566.2024.2446623.Peer-Reviewed Original ResearchConceptsTreatment of substance use disordersSubstance use disordersTreating substance use disordersPsychedelic agentsNarrative reviewReceptor agonistsClinical literatureReceptor antagonistNovel interventionsClinical evidenceFDA approvalPublic health issueDisordersReceptorsAgonistsTreatmentCravingPositive resultsPsychedelicsAbstinenceReviewed literatureAgentsHealth issuesAntagonistPrimary affinityBiomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Monette A, Warren S, Barrett J, Garnett-Benson C, Schalper K, Taube J, Topp B, Snyder A. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee. Journal For ImmunoTherapy Of Cancer 2024, 12: e009427. PMID: 39032943, PMCID: PMC11261685, DOI: 10.1136/jitc-2024-009427.Peer-Reviewed Original ResearchConceptsProgrammed cell death protein 1/programmed death-ligand 1PD-(L)1Biomarker developmentApplication of novel biomarkersPD-(L)1 therapyDeath-ligand 1Patient selection strategiesCombination therapyTumor typesTreatment optionsImmune biologyAxis inhibitionEffective treatmentCancer progressionNovel biomarkersPatientsTherapyImmunotherapyBiomarkersKnowledge of mechanismsDelivery of effective treatmentTreatmentAgentsTumorProgression
2023
Synthetic cooling agent in oral nicotine pouch products marketed as ‘Flavour-Ban Approved’
Jabba S, Erythropel H, Woodrow J, Anastas P, O'Malley S, Krishnan-Sarin S, Zimmerman J, Jordt S. Synthetic cooling agent in oral nicotine pouch products marketed as ‘Flavour-Ban Approved’. Tobacco Control 2023, 34: 106-110. PMID: 37380351, PMCID: PMC10753027, DOI: 10.1136/tc-2023-058035.Peer-Reviewed Original ResearchGas chromatography/mass spectrometryChromatography/mass spectrometryWS-3Oral nicotine pouchesSynthetic coolantsMass spectrometryChemical analysisSensory irritancyFlavor additivesAdditivesChemical contentFlavoring agentProductsIrritant activitySpectrometryFlavourantsEffective strategyExtractAgentsNicotine pouchesWhat’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
Awada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMDS/AML patientsEarly clinical trialsPotential therapeutic agentAML patientsMultidrug combinationsClinical trialsMyeloid leukemiaMyeloid neoplasmsRational approachSingle agentCurrent managementTherapeutic potentialStandardized guidelinesTherapeutic agentsMutational characteristicsPatientsNeoplasmsLatest findingsGenomic factorsCellular adaptationAgentsHMA resistanceFailureLeukemiaNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgents
2022
Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial
Wang SY, Hanna JM, Gongal P, Onuma O, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. American Heart Journal 2022, 254: 30-34. PMID: 35932912, PMCID: PMC10908340, DOI: 10.1016/j.ahj.2022.07.006.Peer-Reviewed Original ResearchConceptsDiastolic hypertensionSystolic hypertensionAntihypertensive agentsSecondary analysisPrevent Heart Attack TrialBroad treatment recommendationsDifferent antihypertensive agentsUse of chlorthalidoneLipid-lowering treatmentHeart Attack TrialCoronary heart diseaseCause mortalityPrimary outcomeAttack TrialALLHAT trialHeart diseaseTreatment recommendationsHypertensionPatientsTrialsAntihypertensivesAmlodipineLisinoprilStrokeAgentsCancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy
2021
Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
Wallach JD, Zhang AD, Skydel JJ, Bartlett VL, Dhruva SS, Shah ND, Ross JS. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. JAMA Network Open 2021, 4: e2133667. PMID: 34751763, PMCID: PMC8579227, DOI: 10.1001/jamanetworkopen.2021.33667.Peer-Reviewed Original ResearchInnovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma
Marchi E, Sawas A, Ma H, Scotto L, Montanari F. Innovative Chemotherapy‐free Approaches for the Treatment of Peripheral T‐Cell Lymphoma. 2021, 367-377. DOI: 10.1002/9781119671336.ch27.Peer-Reviewed Original ResearchPrimary cutaneous T-cell lymphomaT-cell lymphomaHypomethylating agentPeripheral T-cell lymphomaCutaneous T-cell lymphomaChemotherapy-free approachConventional cytotoxic chemotherapyCare of patientsDrug-drug combinationsNew therapeutic agentsCytotoxic chemotherapyPreclinical observationsTherapeutic agentsKinase inhibitorsPhase ICancer medicineProteasome inhibitorsLines of evidenceLymphomaSubsequent developmentInhibitorsDrugsAgentsChemotherapyPatientsChapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Huang Y, Jia H, Bao W. Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021, 367-412. DOI: 10.1016/b978-0-12-816475-4.00013-6.Peer-Reviewed Original ResearchAlzheimer's diseasePathologic featuresApplication of PETDrug developmentSynaptic vesicle protein 2ADifferent pathologic featuresFeatures of neurodegenerationCentral nervous systemAD drug developmentPositron emission tomographyNeuroinflammation biomarkersCholinergic systemΒ-amyloidNervous systemTau proteinEmission tomographyAD researchDiseaseProtein 2AInvestigation of diseasesQuantitative imaging techniquesTomographyImaging techniquesAgentsPET
2020
HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin
Morgan R, Parsad S, Turaga K, Eng O. HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin. Basic & Clinical Pharmacology & Toxicology 2020, 127: 551-553. PMID: 32623784, DOI: 10.1111/bcpt.13464.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyHypersensitivity reactionsSystemic oxaliplatinDiscontinued due to toxicityPlatinum-based chemotherapeutic agentsAlternative routes of administrationPlatinum-based agentsRoute of administrationIntraperitoneal chemotherapySystemic therapyDesensitization protocolCross-reactivityCase reportChemotherapeutic agentsSkin testPatientsCisplatinTherapyOxaliplatinAdverse effectsSafety parametersHypersensitivityPlatinum saltsDesensitizationAgentsCan Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents?
Merriam A, Paidas M. Can Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents? 2020, 223-230. DOI: 10.1201/9780429450303-24.ChaptersRecurrent pregnancy lossPregnancy outcomesAntiplatelet agentsPregnancy lossAntithrombotic agentsMultiple adverse pregnancy outcomesSmall case-control studyAntiplatelet agent aspirinAdverse pregnancy outcomesSuccessful pregnancy outcomeCase-control studyMultiple prospective studiesHistory of thrombophiliaClass of drugsEffects of anticoagulantsAspirin treatmentProspective studyAnticoagulant agentsLive birthsThrombophiliaBlood clotsWomenAspirinOutcomesAgents
2019
Perspective on potential impact of HIV central nervous system latency on eradication.
Chan P, Ananworanich J. Perspective on potential impact of HIV central nervous system latency on eradication. AIDS 2019, 33 Suppl 2: s123-s133. PMID: 31090545, DOI: 10.1097/qad.0000000000002264.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAntiretroviral therapyEarly antiretroviral therapyHIV antiretroviral therapyLife-long adherencePossibility of comorbidityART interruptionCNS persistenceHIV eradicationNeurological safetyTreatment interruptionHIV remissionNeurocognitive disordersRemission studiesExperimental agentsHIVEradicationTherapyRemissionComorbiditiesAgentsDifferentiating spontaneous echo contrast, sludge, and thrombus in the left atrial appendage: Can ultrasound enhancing agents help?
Posada‐Martinez E, Trejo‐Paredes C, Ortiz‐Leon X, Ivey‐Miranda J, Lin BA, McNamara RL, Arias‐Godinez J, Lombo B, Sugeng L. Differentiating spontaneous echo contrast, sludge, and thrombus in the left atrial appendage: Can ultrasound enhancing agents help? Echocardiography 2019, 36: 1413-1417. PMID: 31260135, DOI: 10.1111/echo.14405.Peer-Reviewed Original ResearchContemporary management of spontaneous retroperitoneal and rectus sheath hematomas
Warren MH, Bhattacharya B, Maung AA, Davis KA. Contemporary management of spontaneous retroperitoneal and rectus sheath hematomas. The American Journal Of Surgery 2019, 219: 707-710. PMID: 31109633, DOI: 10.1016/j.amjsurg.2019.05.002.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiographyAnticoagulantsBlood Component TransfusionEmbolization, TherapeuticFemaleHematomaHumansInternational Normalized RatioLength of StayMaleMiddle AgedPlatelet Aggregation InhibitorsProthrombin TimeRectal DiseasesRetroperitoneal SpaceRetrospective StudiesShock, HemorrhagicTomography, X-Ray ComputedConceptsSheath hematomaSurgical interventionBlood product transfusionOptimal treatment strategySpontaneous retroperitonealIntravenous heparinProduct transfusionAdult patientsMedian ageAntiplatelet agentsHemorrhagic shockDisease progressionBlood productsTreatment strategiesCT scanHematomaOutcome dataPatientsOne-year periodContemporary managementSpecific agentsAngioembolizationRetroperitonealInterventionAgentsSo I am Getting a CT for Small Bowel Obstruction, Do I Need Oral Contrast? IV Contrast?
Gettel C, Cummings C. So I am Getting a CT for Small Bowel Obstruction, Do I Need Oral Contrast? IV Contrast? 2019, 175-176. DOI: 10.1007/978-3-319-98343-1_49.Peer-Reviewed Original Researchp53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson F, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf G, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar A, Netto G, Rao P, Sgambato A, Maitra A, Tripathi D, Walker C, Karam J, Heffernan T, Viale A, Roberts C, Msaouel P, Tannir N, Draetta G, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 2019, 35: 204-220.e9. PMID: 30753823, PMCID: PMC7876656, DOI: 10.1016/j.ccell.2019.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAutophagyCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Endoplasmic Reticulum StressFemaleGene Expression Regulation, NeoplasticHumansMaleMice, 129 StrainMice, Inbred C57BLMice, KnockoutProteasome InhibitorsProteostasisProto-Oncogene Proteins c-mycRhabdoid TumorSignal TransductionSMARCB1 ProteinTumor Cells, CulturedTumor Suppressor Protein p53Unfolded Protein ResponseConceptsMalignant rhabdoid tumorRhabdoid tumorUnfolded protein responseClinical pathological featuresAggressive pediatric malignancyCombination of agentsPediatric malignanciesMouse modelP53 axisMosaic mouse modelChromatin remodeling genesER stress responseTumorsHuman oncogenesisBiallelic inactivationMalignancyProtein responseDramatic activationHuman diseasesMaster regulatorExquisite sensitivityAutophagic machineryAgentsDiseaseStress responseChapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.ChaptersExposure Science: Ingestion☆
Deziel N, Freeman N, Hartle J. Exposure Science: Ingestion☆. 2019, 823-832. DOI: 10.1016/b978-0-12-409548-9.10916-9.Peer-Reviewed Original ResearchNondietary ingestion exposurePersistent organic pollutantsOrganic pollutantsIngestion exposureImportance of ingestionIngestion of chemicalsSusceptible populationIngestion exposure pathwayChemical agentsAgents of concernRoute of exposureChemicalsConsumption of foodRoutePathogenic microbial agentsIngestionExposureExposure pathwaysPrimary routeBiological agentsMicrobial agentsPollutantsAgentsMetalsFurther research
2018
Rapid Microbial Antigen Tests
Campbell S, Landry M. Rapid Microbial Antigen Tests. 2018, 99-125. DOI: 10.1007/978-3-319-33900-9_5.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply